Bristol-Myers: Biocon Biologics to expand biosimilar oncology portfolio, outline strategic vision at the 2026 J.P. Morgan Healthcare Conference (53.06)
- The company is set to unveil three new biosimilar oncology assets—Trastuzumab/Hyaluronidase - Herceptin SC/Herceptin HYLECTA (RHHBY), Nivolumab - Opdivo (BMY), and Pembrolizumab - Keytruda (MRK) —at the 2026 J.P. Morgan Healthcare Conference.
- With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics' existing portfolio of 17 oncology medications, which includes Pertuzumab (Perjeta) that was recently submitted to the FDA, as well as several small molecule cancer therapies.